drug · small molecule
daridorexant hydrochloride
Marketedupdated 3mo agoby Idorsia Pharmaceutical Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1Small molecule drug with a maximum clinical stage of Approval, with an approval for insomnia.
targets
Orexin receptor type 2Orexin/Hypocretin receptor type 1
all catalysts(1)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 7, 2027
239 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Dec 2, 2034method-of-use (U-620)US 10023560
- Dec 2, 2034method-of-use (U-620)US 10023560
- Dec 2, 2034compositionUS 9790208
- Dec 2, 2034compositionUS 9790208
- Jun 12, 2033compositionUS 9732075
- Jun 12, 2033compositionUS 9732075
FDA exclusivities (6)
- Sep 30, 2027M-200Method (3y)1.1y
- Sep 30, 2027M-310Method (3y)1.1y
- Sep 30, 2027M-200Method (3y)1.1y
- Sep 30, 2027M-310Method (3y)1.1y
- Apr 7, 2027NCENew Chemical Entity (5y)239d
- Apr 7, 2027NCENew Chemical Entity (5y)239d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that